• Explore /
  • Poster
  • / Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).

Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).

Abstract Poster

Authors

Richard Adams

Richard Adams

Velindre Hospital

Richard Adams , David Fisher , Susan Farragher , Bharat Jasani , Christopher Smith , Michelle James , Jeremy Cheadle , Laura Nichols , Angela Meade , Richard Kaplan , Richard Wilson , Harpreet Wasan , Tim Maughan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 Markers in Cancer

Session Type

Poster Session

Session Title

General Poster Session A

Track

Clinical Evaluation of Biomarkers,Imaging Biomarkers,Immune System and Immunotherapeutic Markers

Sub Track

Biomarker Readiness for Clinical Application

Clinical Trial Registration Number

ISRCTN27286448

Citation

J Clin Oncol 30: 2012 (suppl 30; abstr 32)

Abstract #

32

Poster Bd #

A1

Abstract Disclosures

Similar Posters

First Author: Richard A. Adams

First Author: Sebastian Stintzing

First Author: Ho Min Kim

First Author: Christopher Williams